Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPtivate-6: Maplirpacept + Glofitamab + Obinutuzumab in R/R DLBCL
NCT05896163Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Aug 2023
- Primary completion
- Apr 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
A Phase 2 trial of maplirpacept in diffuse large B-cell lymphoma (DLBCL), sponsored by Pfizer. Started Aug 2023; status: terminated.
02
Drugs
maplirpacept
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05896163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896163.